Compare Illinois Tool Works Inc. (ITW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Illinois Tool Works Inc. trades at $263.78 (market cap $74.38B), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: Illinois Tool Works Inc. is far larger — about 7.4× State Street SPDR S&P Biotech ETF's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ITW | XBI | |
|---|---|---|
Market Cap | $74.38B | $10.11B |
Volume | 1,125,477 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $299.60 | $169.55 |
52-Week Low | $241.07 | $104.99 |
Typical Hold Time | 67 Days | 38 Days |
Enterprise Value | $83.23B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.13, up 1.14% today, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and three consecutive quarterly EPS beats. The stock is supported by a $1.72 quarterly dividend and a consensus price target of $276.86, though analyst ratings are mixed with 21.43% buy, 46.43% hold, and 32.14% sell. Recent news highlights its Dividend King status and institutional buying interest.
The outlook balances robust profitability and dividend reliability against technical weakness and modest revenue growth. Upside potential exists if earnings momentum continues, but risks include high valuation multiples and sector-specific headwinds. The stock presents a hold case for income-focused investors awaiting clearer technical improvement.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
